|
|
Article: ANAVEX contracts FORENAP Pharma for clinical trials of ANAVEX 2-73 in Alzheimers disease.
- Article from:
- Cancer Weekly
- Article date:
- November 17, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Anavex Life Sciences Corp. ("ANAVEX" or the "Company") (OTCBB: AVXL) has selected FORENAP Pharma EURL ("FORENAP") as the contract research organization (CRO) for Phase I clinical trials of ANAVEX 2-73, the company's lead Alzheimer's drug candidate. FORENAP has been involved in pre-clinical and clinical research for 20 years and is renowned for its expertise in Central Nervous System (CNS) studies, including Alzheimer's disease (see also Central Nervous System Disorders).
"The selection of a world-class CRO is an important milestone in our product development process and it underscores our commitment to advance ANAVEX 2-73 through Phase I clinical trials," said ...